AM-Pharma is acquired by Ambrose Healthcare
The UK-headquartered rare disease specialist takes over the ilofotase alfa programme for adults with hypophosphatasia, a patient group with unmet medical need.
See the latest news and media coverage for AM-Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing therapies for rare diseases
am-pharma.comLast updated
The UK-headquartered rare disease specialist takes over the ilofotase alfa programme for adults with hypophosphatasia, a patient group with unmet medical need.
Juliane Bernholz outlines in European Biopharmaceutical Review how therapies can address adult patients' pain, fatigue and bone weakness, aligning with AM-Pharma's ilofotase alfa development.
She discusses launch and commercialisation strategy for European biopharma, highlighting ilofotase alfa, its investigational hypophosphatasia therapy with FDA and EMA orphan drug designation.
She will discuss musculoskeletal health and ilofotase alfa, its enzyme replacement therapy for adult hypophosphatasia, which has positive Phase 1b data and is Phase 3 ready.
, Oct. 20, 2026 (GLOBE NEWSWIRE) -- CAMBRIDGE, UK & UTRECHT, THE NETHERLANDS - October 20, 2026 - Ambrose Healthcare, a rare disease specialist, has...
Ambrose Healthcare has bought AM-Pharma for up to 161 million euros ($181 million), inking a cut-price deal for the Dutch biotech once courted by Pfizer...
AM-Pharma identified "encouraging data for preserving kidney function." (Ekkaluck/iStock/Getty Images Plus) Pfizer may have dodged a bullet by walking away from AM-Pharma. The biotech, a...
The Utrecht-based pharmaceutical company AM-Pharma has closed a million-dollar deal with a Japanese industry colleague regarding the sales rights for a drug against acute kidney failure. The value of the...
Track AM-Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AM-Pharma and other trending companies.